Search clinical trials for: BI 1034020

Total 1219 results

Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Terminated

High-Dose Y-90-Ibritumomab Tiuxetan Added to Reduced-Intensity Allogeneic Stem Cell Transplant Regimen for Relapsed or Refractory Aggressive B-Cell Lymphoma

Recurrent Adult Diffuse Large Cell Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Post-Transplant Lymphoproliferative Disorder | Recurrent Burkitt Lymphoma | Refractory Burkitt Lymphoma

United States
National Cancer Institute (NCI)

Active, not recruiting

Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Anemia | Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

United States
National Cancer Institute (NCI)
NRG Oncology

Completed

Bevacizumab With or Without Fosbretabulin Tromethamine in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma

United States
National Cancer Institute (NCI)
Fox Chase Cancer Center

Completed

Temsirolimus and Bevacizumab in Treating Patients With Stage III or Stage IV Malignant Melanoma (Mel47)

Stage IV Skin Melanoma | Recurrent Melanoma | Stage IIIB Skin Melanoma | Stage IIIC Skin Melanoma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Olaparib and High-Dose Chemotherapy in Treating Patients With Relapsed or Refractory Lymphomas Undergoing Stem Cell Transplant

Refractory Hodgkin Lymphoma | Refractory T-Cell Non-Hodgkin Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Recurrent T-Cell Non-Hodgkin Lymphoma

United States
University of California, San Francisco
Merck Sharp & Dohme LLC

Completed

Pembrolizumab, Capecitabine, and Bevacizumab in Treating Patients With Microsatellite Stable Colorectal Cancer That Is Locally Advanced, Metastatic, or Cannot Be Removed by Surgery

Stage IV Colorectal Cancer AJCC v7 | Stage IVA Colorectal Cancer AJCC v7 | Stage IVB Colorectal Cancer AJCC v7 | Microsatellite Stable | Stage III Colorectal Cancer AJCC v7 | Stage IIIB Colorectal Cancer AJCC v7 | Stage IIIC Colorectal Cancer AJCC v7 | Mismatch Repair Protein Proficient

United States
National Cancer Institute (NCI)

Completed

Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer

Uterine Carcinosarcoma | Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Recurrent Uterine Corpus Carcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Seromucinous Carcinoma | Endometrial Serous Adenocarcinoma | Lung Carcinoid Tumor | Metastatic... and other conditions

United States, Canada
Boehringer Ingelheim

Completed

The Effect of BI 187004 on the Pharmacokinetics of Cytochrome P450 Substrates (Caffeine, Warfarin, Omeprazole, Metoprolol and Midazolam) and a P Glycoprotein Substrate (Digoxin)

Healthy

Germany
National Cancer Institute (NCI)

Recruiting

Comparing the Effectiveness of the Immunotherapy Agents Rituximab or Mosunetuzumab in Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma

Nodular Lymphocyte Predominant B-Cell Lymphoma | Recurrent Nodular Lymphocyte Predominant B-Cell Lymphoma | Refractory Nodular Lymphocyte Predominant B-Cell Lymphoma

United States
National Cancer Institute (NCI)

Completed

Bevacizumab and Interleukin-2 in Treating Patients With Metastatic Kidney Cancer

Recurrent Renal Cell Carcinoma | Stage IV Renal Cell Cancer

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing the Addition of an Immunotherapy Agent, Atezolizumab, When Given With the Usual Chemo-Immunotherapy Drug Combination (Rituximab Plus Gemcitabine and Oxaliplatin) for Relapsed/Refractory (That Has Come Back or Not Responded to Treatment) Transformed Diffuse Large B-Cell Lymphoma

Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Recurrent Transformed Non-Hodgkin Lymphoma | Richter Syndrome | Refractory Transformed Non-Hodgkin Lymphoma | Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Withdrawn

Vorinostat and Combination Chemotherapy Before Donor Stem Cell Transplantation for the Treatment of Relapsed Aggressive B-cell or T-cell Non-Hodgkin Lymphoma

Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Recurrent T-Cell Non-Hodgkin Lymphoma | Recurrent High Grade B-Cell Lymphoma | Recurrent Aggressive Non-Hodgkin Lymphoma | Recurrent Burkitt Lymphoma | Recurrent Transformed B-Cell Non-Hodgkin Lymphoma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Engineered Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies

Acute Myeloid Leukemia | Recurrent Hodgkin Lymphoma | Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Chronic Myelomonocytic Leukemia | Acute Lymphoblastic Leukemia | Lymphoblastic Lymphoma | Myelodysplastic Syndrome | Plasma Cell Myeloma | Aplastic Anemia | Recurrent Non-Hodgkin... and other conditions

United States
National Cancer Institute (NCI)

Completed

Bortezomib, Rituximab, and Dexamethasone With or Without Temsirolimus in Treating Patients With Untreated or Relapsed Waldenstrom Macroglobulinemia or Relapsed or Refractory Mantle Cell or Follicular Lymphoma

Recurrent Mantle Cell Lymphoma | Recurrent Marginal Zone Lymphoma | Recurrent Small Lymphocytic Lymphoma | Recurrent Non-Hodgkin Lymphoma | Refractory Non-Hodgkin Lymphoma | Refractory Mantle Cell Lymphoma | Refractory Small Lymphocytic Lymphoma | Recurrent Follicular Lymphoma | Refractory Follicular... and other conditions

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Unknown

NK Cells in Cord Blood Transplantation

Recurrent Hodgkin Lymphoma | Refractory Hodgkin Lymphoma | Secondary Acute Myeloid Leukemia | Myelodysplastic Syndrome | Recurrent Acute Myeloid Leukemia | Recurrent Small Lymphocytic Lymphoma | Refractory Chronic Lymphocytic Leukemia | Recurrent Non-Hodgkin Lymphoma | Refractory Non-Hodgkin Lymphoma | Recurrent Acute Lymphoblastic Leukemia and other conditions

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

Brigatinib and Bevacizumab for the Treatment of ALK-Rearranged Locally Advanced, Metastatic, or Recurrent NSCLC

Metastatic Lung Non-Small Cell Carcinoma | Stage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Stage III Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Stage IIIC Lung Cancer AJCC v8 | Locally Advanced Lung Non-Small... and other conditions

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Radiation Therapy in Treating Patients With Recurrent Brain Tumors Who Have Undergone Previous Radiation Therapy

Recurrent Brain Neoplasm

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Bendamustine With or Without Cyclophosphamide in Preventing GVHD in Patients Undergoing Stem Cell Transplant

Hematopoietic and Lymphoid System Neoplasm

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

CMC-544 and Allogeneic Transplantation for CD22 Positive-Lymphoid Malignancies

Hematopoietic and Lymphoid Cell Neoplasm

United States
GOG Foundation
National Cancer Institute (NCI)

Completed

Bevacizumab With or Without Everolimus in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma

United States
National Cancer Institute (NCI)

Terminated

Everolimus With or Without Bevacizumab in Treating Patients With Advanced Kidney Cancer That Progressed After First-Line Therapy

Clear Cell Renal Cell Carcinoma | Recurrent Renal Cell Carcinoma | Stage III Renal Cell Cancer AJCC v7 | Stage IV Renal Cell Cancer AJCC v7

United States
Hyunseok Kang, MD
NRG Oncology

Completed

Sodium Thiosulfate in Preventing Ototoxicity for Squamous Cell Cancer Patients Undergoing Chemoradiation With Cisplatin

Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Stage III Hypopharyngeal Carcinoma AJCC v8 | Stage III Laryngeal Cancer AJCC v8 | Stage III Lip and Oral Cavity Cancer AJCC v8 | Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8 | Stage IV Hypopharyngeal... and other conditions

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Bevacizumab, Capecitabine, and Oxaliplatin in Treating Advanced Small Intestinal or Ampulla of Vater Adenocarcinoma

Small Intestinal Adenocarcinoma | Stage III Small Intestinal Adenocarcinoma AJCC v8 | Stage IIIA Small Intestinal Adenocarcinoma AJCC v8 | Stage IIIB Small Intestinal Adenocarcinoma AJCC v8 | Stage IV Small Intestinal Adenocarcinoma AJCC v8 | Ampulla of Vater Adenocarcinoma | Stage III Ampulla... and other conditions

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Terminated

Paclitaxel and Bevacizumab With or Without Emactuzumab in Treating Patients With Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Seromucinous Carcinoma | Ovarian Undifferentiated Carcinoma | Ovarian Clear Cell Adenocarcinoma | Ovarian Mucinous Adenocarcinoma | Fallopian Tube... and other conditions

United States
University of Nebraska
National Cancer Institute (NCI)

Terminated

Bevacizumab and Ascorbic Acid in Patients Treating With Recurrent High Grade Glioma

Glioma | Glioblastoma

United States
Boehringer Ingelheim

Completed

Effects of BI 201335 NA on Cytochrome P450 and P-glycoprotein Activity Using a Probe Drug Cocktail in Healthy Volunteers

Healthy
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors

Recurrent Peritoneal Malignant Mesothelioma | Recurrent Pleural Malignant Mesothelioma | Vaginal Squamous Cell Carcinoma, Not Otherwise Specified | Neuroendocrine Carcinoma | Pancreatic Neuroendocrine Tumor | Recurrent Merkel Cell Carcinoma | Recurrent Nasopharynx Carcinoma | Appendix Adenocarcinoma and other conditions

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Nivolumab With or Without Bevacizumab or Ipilimumab Before Surgery in Treating Patients With Metastatic Kidney Cancer That Can Be Removed by Surgery

Clear Cell Renal Cell Carcinoma | Stage IV Renal Cell Cancer AJCC v7 | Metastatic Kidney Carcinoma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

First-Line Treatment of Bevacizumab, Carboplatin, and Paclitaxel in Treating Participants With Stage III-IV Ovarian, Primary Peritoneal, and Fallopian Tube Cancer

Ovarian Endometrioid Adenocarcinoma | Ovarian Seromucinous Carcinoma | Ovarian Undifferentiated Carcinoma | Fallopian Tube Carcinoma | Ovarian Clear Cell Adenocarcinoma | Ovarian Mucinous Adenocarcinoma | Fallopian Tube Transitional Cell Carcinoma | Ovarian Transitional Cell Carcinoma | Fallopian Tube... and other conditions

United States
National Cancer Institute (NCI)

Completed

Bevacizumab and Low-Dose Cyclophosphamide in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cancer

Recurrent Ovarian Carcinoma | Primary Peritoneal Carcinoma | Stage IV Ovarian Cancer

United States
Wake Forest University Health Sciences
National Cancer Institute (NCI)

Active, not recruiting

Tailored Prednisone Reduction in Preventing Hyperglycemia in Participants With B-Cell Non-Hodgkin Lymphoma Receiving Combination Chemotherapy Treatment

B-Cell Non-Hodgkin Lymphoma

United States
University of Washington
National Cancer Institute (NCI)

Completed

Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

Acute Lymphoblastic Leukemia | Lymphoblastic Lymphoma

United States
Roswell Park Cancer Institute

Completed

Pembrolizumab, Bevacizumab, and Cyclophosphamide in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Clear Cell Adenocarcinoma | Ovarian Mucinous Adenocarcinoma | Fallopian Tube Clear Cell Adenocarcinoma | Fallopian Tube Endometrioid Adenocarcinoma and other conditions

United States
National Cancer Institute (NCI)

Completed

Bevacizumab and Irinotecan in Treating Young Patients With Recurrent, Progressive, or Refractory Glioma, Medulloblastoma, Ependymoma, or Low Grade Glioma

Recurrent Childhood Medulloblastoma | Recurrent Childhood Ependymoma | Recurrent Childhood Brain Stem Glioma | Childhood Spinal Cord Neoplasm | Childhood Oligodendroglioma | Childhood Cerebral Anaplastic Astrocytoma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Personalized NK Cell Therapy in CBT

Recurrent Hodgkin Lymphoma | Chronic Myelomonocytic Leukemia | Previously Treated Myelodysplastic Syndrome | Recurrent Adult Acute Myeloid Leukemia | Acute Lymphoblastic Leukemia | Secondary Acute Myeloid Leukemia | Myelodysplastic Syndrome | Recurrent Acute Myeloid Leukemia | Myelodysplastic Syndrome... and other conditions

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients With Leukemia or Lymphoma

Acute Myeloid Leukemia | Hodgkin Lymphoma | Recurrent Hodgkin Lymphoma | Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Chronic Myelomonocytic Leukemia | Acute Lymphoblastic Leukemia | Chronic Lymphocytic Leukemia | Non-Hodgkin Lymphoma | Acute Leukemia | Myelodysplastic Syndrome | Refractory Myelodysplastic Syndrome and other conditions

United States
Northwestern University
Bristol-Myers Squibb; National Cancer Institute (NCI)

Suspended

Nivolumab and Combination Chemotherapy in Treating Participants With Diffuse Large B-Cell Lymphoma

B-Cell Non-Hodgkin Lymphoma | Primary Mediastinal (Thymic) Large B-Cell Lymphoma | CD20 Positive | Aggressive Non-Hodgkin Lymphoma | Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma | Diffuse Large B-Cell Lymphoma Unclassifiable | Intravascular Large B-Cell Lymphoma | T-Cell/Histiocyte-Rich...

United States
SWOG Cancer Research Network
National Cancer Institute (NCI)

Terminated

S0819: Carboplatin and Paclitaxel With or Without Bevacizumab and/or Cetuximab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer

Recurrent Squamous Cell Lung Carcinoma | Recurrent Lung Adenocarcinoma | Stage IV Lung Adenocarcinoma | Recurrent Large Cell Lung Carcinoma | Stage IV Squamous Cell Lung Carcinoma | Stage IV Large Cell Lung Carcinoma

United States, Mexico
Academic and Community Cancer Research United
National Cancer Institute (NCI)

Completed

Erlotinib Hydrochloride With or Without Bevacizumab in Treating Patients With Stage IV Non-small Cell Lung Cancer With Epidermal Growth Factor Receptor Mutations

Lung Non-Squamous Non-Small Cell Carcinoma | Stage IV Lung Non-Small Cell Cancer AJCC v7 | EGFR Exon 19 Deletion Mutation | EGFR NP_005219.2:p.L858R

United States
National Cancer Institute (NCI)
NRG Oncology

Completed

Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

Ovarian Endometrioid Adenocarcinoma | Ovarian Clear Cell Adenocarcinoma | Ovarian Mucinous Adenocarcinoma | Fallopian Tube Transitional Cell Carcinoma | Ovarian Transitional Cell Carcinoma | Fallopian Tube Clear Cell Adenocarcinoma | Fallopian Tube Endometrioid Adenocarcinoma | Fallopian Tube Mucinous... and other conditions

United States, Korea, Republic of, Canada, Japan
Joseph Tuscano
National Cancer Institute (NCI); ADC Therapeutics S.A.

Recruiting

Loncastuximab Tesirine and Rituximab Followed by DA-EPOCH-R for Treating Patients With High-Risk Diffuse Large B-cell Lymphoma

High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements | High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements | Double-Expressor Lymphoma | High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements

United States
OHSU Knight Cancer Institute
AbbVie; Oregon Health and Science University

Recruiting

Venetoclax, Dasatinib, Prednisone, Rituximab and Blinatumomab for the Treatment of Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia or Mixed Phenotype Acute Leukemia

B Acute Lymphoblastic Leukemia | Recurrent B Acute Lymphoblastic Leukemia | Recurrent Mixed Phenotype Acute Leukemia | B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 | Mixed Phenotype Acute Leukemia

United States
M.D. Anderson Cancer Center

Recruiting

PACIFIC: Primary Mediastinal Large B-cell Lymphoma Treated With Antibody Therapy, Checkpoint Inhibitor in Frontline With ImmunoChemotherapy (PACIFIC)

Ann Arbor Stage I Primary Mediastinal (Thymic) Large B-Cell Lymphoma | Ann Arbor Stage II Primary Mediastinal (Thymic) Large B-Cell Lymphoma | Ann Arbor Stage III Primary Mediastinal (Thymic) Large B-Cell Lymphoma | Ann Arbor Stage IV Primary Mediastinal (Thymic) Large B-Cell Lymphoma

United States
University of Washington
National Cancer Institute (NCI)

Completed

Pembrolizumab and Combination Chemotherapy in Treating Patients With Previously Untreated Diffuse Large B-cell Lymphoma or Grade 3b Follicular Lymphoma

Grade 3b Follicular Lymphoma | Stage III Follicular Lymphoma | Composite Lymphoma | Stage I Diffuse Large B-Cell Lymphoma | Stage I Follicular Lymphoma | Stage II Diffuse Large B-Cell Lymphoma | Stage II Follicular Lymphoma | Stage III Diffuse Large B-Cell Lymphoma | Stage IV Diffuse Large B-Cell Lymphoma and other conditions

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Bortezomib and Vorinostat as Maintenance Therapy After Autologous Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma

Follicular Lymphoma | Mantle Cell Lymphoma | Non-Hodgkin Lymphoma | B-Cell Non-Hodgkin Lymphoma | Adult Diffuse Large B-Cell Lymphoma | T-Cell Non-Hodgkin Lymphoma

United States
Academic and Community Cancer Research United
National Cancer Institute (NCI)

Active, not recruiting

Capecitabine and Bevacizumab With or Without Atezolizumab in Treating Patients With Refractory Metastatic Colorectal Cancer

Stage IV Colorectal Cancer AJCC v7 | Stage IVA Colorectal Cancer AJCC v7 | Stage IVB Colorectal Cancer AJCC v7 | Recurrent Colorectal Carcinoma | Metastatic Colorectal Carcinoma | Refractory Colorectal Carcinoma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Bevacizumab and Atezolizumab With or Without Cobimetinib in Treating Patients With Untreated Melanoma Brain Metastases

Metastatic Melanoma | Clinical Stage IV Cutaneous Melanoma AJCC v8 | Pathologic Stage IV Cutaneous Melanoma AJCC v8 | Metastatic Malignant Neoplasm in the Brain | Refractory Melanoma | BRAF V600 Wild Type | Intracranial Melanoma

United States
University of Washington
Incyte Corporation

Recruiting

Chemotherapy (DA-EPOCH+/-R) and Targeted Therapy (Tafasitamab) for the Treatment of Newly-Diagnosed Philadelphia Chromosome Negative B Acute Lymphoblastic Leukemia

B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Withdrawn

CAR.CD19-CD28-zeta-2A-iCasp9-IL15-Transduced Cord Blood NK Cells, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Participants With B-cell Lymphoma

Mantle Cell Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Recurrent Follicular Lymphoma | Refractory Follicular Lymphoma | CD19 Positive

United States
M.D. Anderson Cancer Center

Recruiting

Atezolizumab and Bevacizumab Before Surgery for the Treatment of Resectable Liver Cancer

Stage IB Hepatocellular Carcinoma AJCC v8 | Stage II Hepatocellular Carcinoma AJCC v8 | Resectable Hepatocellular Carcinoma | Stage I Hepatocellular Carcinoma AJCC v8 | Stage IA Hepatocellular Carcinoma AJCC v8

United States

Search clinical trials for: BI 1034020

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Montenegro

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations